Ulcerative colitis, one of the two major forms of inflammatory bowel disease alongside Crohn’s disease, affects millions of people worldwide, and its incidence continues to climb, particularly in newly industrialized regions. Current pharmacological options, ranging from aminosalicylates to biologics, are limited by incomplete efficacy, high cost, and adverse effects. The research team, led by Sumin Wang and Wanneng Wang of Chongqing University of Technology together with collaborators at Xinqiao Hospital of Army Medical University and the General Hospital of Western Theater Command, set out to determine whether DHA, a long-chain omega-3 polyunsaturated fatty acid that must be obtained largely through diet, could serve as a safe nutritional complement to existing therapies, and if so, how it works.

The experimental design centered on the dextran sulfate sodium, or DSS, model of colitis, a widely used approach in which mice drink water containing DSS for seven consecutive days to induce epithelial injury that closely mimics human ulcerative colitis. Eight-week-old male C57BL/6 mice received DHA by oral gavage at a dose of 35 milligrams per kilogram per day, suspended in corn oil, throughout the experiment. A group treated with sulfasalazine, a standard clinical drug for ulcerative colitis, served as a positive control. The results were striking. Compared with untreated colitic mice, the DHA-treated animals lost significantly less body weight, showed improved survival, and registered lower scores on the disease activity index, a composite measure of weight loss, stool consistency, and visible blood in the stool. Their colons were also measurably longer, reflecting reduced inflammatory contraction of the tissue.

Histopathology told the same story at the cellular level. Under the microscope, the colons of DSS-treated mice displayed extensive epithelial damage, disruption of the crypt glandular architecture, loss of mucus-producing goblet cells, and dense infiltration of inflammatory cells into the mucosa. DHA supplementation visibly blunted these changes, and quantitative histological scoring confirmed the improvement. Molecular analysis by quantitative real-time polymerase chain reaction showed that DHA also suppressed the colonic expression of pro-inflammatory cytokines, including interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha, the signaling molecules that drive much of the tissue destruction in inflammatory bowel disease.

The pivotal question, however, was whether these benefits required the gut microbiota. To answer it, the researchers depleted the intestinal microbes of a parallel group of mice using a five-day course of a broad-spectrum antibiotic cocktail containing ampicillin, neomycin sulfate, metronidazole, and vancomycin before inducing colitis. The outcome was decisive: in microbiota-depleted mice, DHA lost essentially all of its protective effect. Body weight loss, survival, disease activity scores, colon length, and histological injury were indistinguishable between antibiotic-treated mice that received DHA and those that did not. In other words, when the microbial community was absent, the fatty acid had nothing to work through, strongly implying that resident gut bacteria are required for DHA’s anti-colitic action.

To confirm this interpretation from the opposite direction, the team performed fecal microbiota transplantation. Donor mice were subjected to DSS-induced colitis with or without DHA treatment, and their fecal bacteria were transferred by oral gavage to recipient mice whose own microbiota had been depleted with antibiotics. Recipients that received bacteria from DHA-treated donors developed significantly milder colitis than recipients of bacteria from colitic donors, with reduced weight loss, better survival, longer colons, and less histological damage. The protection, in effect, was transferable along with the microbes, demonstrating that DHA-induced changes in the microbial community are not merely correlated with protection but are sufficient to confer it.

High-throughput sequencing of the bacterial 16S ribosomal RNA gene revealed exactly how DHA reshaped the gut ecosystem. The V3-V4 hypervariable regions of the gene were amplified and sequenced on an Illumina NovaSeq 6000 platform, and the resulting reads were processed through the QIIME2 pipeline with DADA2 denoising and classification against the Greengenes database. Alpha diversity metrics such as the Chao1, Shannon, and ACE indices showed that DHA altered microbial richness, while principal coordinate analysis based on Bray-Curtis and Jaccard distances revealed a clear separation of community structure between DHA-treated and untreated colitic mice. At the genus level, DHA increased the abundance of Bifidobacterium and Ruminococcus_torques_group while reducing Ileibacterium and Ruminococcaceae_UCG_014. Linear discriminant analysis effect size analysis further identified Bifidobacterium and Tyzzerella as taxa enriched in DHA-treated mice, whereas Desulfovibrio, Lactobacillus, and Ruminococcaceae_UCG_010 were enriched in the colitic group. The enrichment of Bifidobacterium is particularly noteworthy, since species such as Bifidobacterium longum and Bifidobacterium bifidum have previously been shown to alleviate experimental colitis and strengthen epithelial barrier function.

The study then connected the microbiota to the intestinal barrier, whose breakdown is a hallmark of ulcerative colitis. Using a fluorescein isothiocyanate-dextran permeability assay, in which mice ingest a fluorescent tracer whose appearance in the bloodstream indicates how leaky the gut has become, the researchers showed that DHA significantly reduced DSS-induced intestinal permeability. Western blotting and immunohistochemistry confirmed that DHA restored the colonic expression and proper localization of the tight junction proteins occludin and zonula occludens-1, the molecular clasps that seal the gaps between adjacent epithelial cells. Crucially, this barrier-protective effect vanished in antibiotic-treated mice and was reproduced in recipient mice that received fecal transplants from DHA-treated donors, demonstrating that even the physical repair of the epithelial lining runs through the microbiota.

Mucosal immunity completed the picture. Regulatory T cells, identified by flow cytometry as CD4-positive cells co-expressing CD25 and the transcription factor Foxp3, are the immune system’s brakes, restraining excessive inflammatory responses and maintaining tolerance to harmless antigens in the gut. DHA treatment increased the frequency of these cells in the colonic lamina propria from 2.66 percent to 4.24 percent in colitic mice. Once again, microbiota depletion abolished this effect, with no significant difference between antibiotic-treated groups, while fecal transplantation from DHA-treated donors raised Treg frequency in recipients to 5.23 percent compared with 1.69 percent in controls. The findings sketch a coherent model in which DHA remodels the gut microbial community, which in turn restores tight junction integrity and expands regulatory T cell populations, together dampening the cytokine storm that drives colonic tissue damage.

The authors are careful to acknowledge the limitations of their work. The specific bacterial species and microbial metabolites that mediate the protective effects remain unidentified, and the study relied on an acute model of colitis rather than chronic disease. Whether Bifidobacterium directly causes the observed phenotype will require bacterial isolation, mono-colonization experiments, or targeted supplementation studies, and the results will need validation in chronic colitis models and eventually in human clinical trials before DHA can be recommended as a therapeutic adjunct for ulcerative colitis. Nevertheless, the study’s functional design, combining antibiotics, fecal transplantation, sequencing, barrier assays, and immune profiling, provides an unusually complete chain of evidence linking a dietary fatty acid to gut microbes, epithelial repair, and immune regulation.

For patients and clinicians, the implications are tentative but tantalizing. Epidemiological studies have long suggested an inverse relationship between omega-3 intake and inflammatory bowel disease risk, and Mendelian randomization analyses have hinted at a causal protective role, but mechanistic proof has been scarce. By showing that the anti-colitic effect of DHA is microbiota-dependent, transferable, and accompanied by enrichment of beneficial taxa such as Bifidobacterium, the Chongqing-based team has elevated DHA from a general anti-inflammatory supplement to a candidate microbiota-targeting intervention. If future studies identify the precise microbial mediators and metabolites involved, DHA or combinations of DHA with targeted probiotics could become a rational, low-toxicity dietary strategy for the prevention or adjunctive treatment of ulcerative colitis, addressing a disease for which safer, more affordable options are urgently needed.